🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Eugenia Gianos MD Tia Bimal Dan Soffer Michael D. Shapiro Ben hirsh Guy Mintz ASPC National Lipid Association Northwell Health NLA Women In Lipidology American College of Cardiology #Grateful for the opportunity to work with such a talented all-🌟 group pubmed.ncbi.nlm.nih.gov/39070027/ Daisy Sahoo Anandita Agarwala Kulkarni, MD FACC Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA Iftikhar J. Kullo #CVPrevention #LPA #StatinIntolerance #KnowFH #LDL #APOB #PCSK9 #PrecisionLipidClinic MCWcardiology

We are happy to support National Lipid Association for National #CholesterolEducationMonth with this week's Tuesday Tweetorial featuring key info you should know about your lipids & lipid testing - the what, who, when, where, & why. Read it now! Thanks National Lipid Association! #LipidXcellence

Great idea National Lipid Association Christie Ballantyne to have clinicians and patients engage with Thomas Dayspring and other faculty and experts to ask their questions! Eugenia Gianos MD Dan Soffer

Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association - Journal of Clinical Lipidology lipidjournal.com/article/S1933-…

National Lipid Association ⚠️measurement of #LPA levels at least once in every adult #CholesterolMonth #LipidXcellence Erin D. Michos, M.D. Dr. Laxmi Mehta Amit Khera Don Lloyd-Jones Dinesh Kalra, MD Gina Lundberg MD FACC FAHA Michael Wilkinson Archna Bajaj Michael D. Shapiro Michael Davidson MD Michael Boffa

Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association Journal of Clinical Lipidology Dan Soffer Christie Ballantyne Jessica Peña Seth Martin - 👏 lipidjournal.com/article/S1933-… Highlights 👉 ➡️ApoB

Exercise enhances the effect of weight loss on lipoprotein lipids. The amount of exercise needed for weight loss and maintenance is greater than what is needed for general health (>200 min/week). Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA #NLA2024 National Lipid Association Beth Jackson

This is a phenomenal document and I would recommend those in the CV prevention space take a look. “Make sure you’re treating the right people, even though you might be treating the same total number of people” Dan Soffer presenting at National Lipid Association #NLAFallCLU

Excellent National Lipid Association sessions today on importance of measuring ApoB, U/S for carotid plaque, CACS, CCTA for coronary plaque assessment in primary prevention #ARTCAP, polygenic risk scores, and lipid lowering in older pts (>75 yrs). Not to be missed! vijay nambi Michael Wilkinson

Congrats to National Lipid Association and the manuscript authors for this timely resource on #apoB. Great presentation today by Dan Soffer, delivering key points around interpretation of apoB for patient care Nicholas Marston Jessica Peña Seth Martin Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA Salim Virani Christie Ballantyne

Great session National Lipid Association: polygenic risk scoring, CAC, carotid imaging, & CCTA at NLA CLU Detect plaque earlier in life and intensify treatment Dinesh Kalra, MD vijay nambi Jacqueline Dron, PhD Dr. James Underberg Michael J. Blaha Ron Blankstein Brittany Weber Dr. Michael Garshick Michael D. Shapiro Christie Ballantyne

🥕 At NLA CLU ‘24 we discussed diet & Lp(a) Sharing this thread I prepared last year. Take away: best approach currently may be to replace sat fats with MUFAs & PUFAs - Med diet is a great choice National Lipid Association Kristina Petersen Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA Christie Ballantyne Harpreet Bhatia Marlys Koschinsky

Dear Twitter/X, thank you for noticing our apoB paper. In an effort to release it coincident with our Fall CLU, the infographic draft was inadvertently released. Please keep an eye out for the final product and apologies for the miscommunication. Thanks for the feedback!

Honored to be a part of the @NationalLipid Association's Expert Clinical Consensus on the Role of ApoB in the Clinical Management of Cardiovascular Risk in Adults. When should we be checking apoB? How low should we go? See link and thread below... lipidjournal.com/article/S1933-…

->ApoB is the main structural protein found on all atherogenic lipoproteins ->There is a single apoB molecule found on each atherogenic lipoprotein: LDL, VLDL, Lp(a), etc ->Thus, apoB is a direct measure of the circulating burden of atherogenic lipoprotein particles

->LDL-C only measures the cholesterol on LDL particles ->Non-HDL-C measures the cholesterol on all atherogenic particles ->ApoB measures the # of all atherogenic particles ->These are highly correlated measures, but apoB can vary by 30-40 mg/dl at a given level of LDL-C...

->As a result, discordance between apoB and LDL-C (or non-HDL-C) is common ->When discordance is present, apoB is the strongest predictor of ASCVD risk, followed by non-HDL-C, with LDL-C being the least predictive of the 3 measure ->Discordance w/ low apoB > w/ high apoB...

->What about patients with discordantly high apoB? ->These patients are at greater risk than appreciated by LDL-C alone & warrant intensification of lipid lowering therapy ->In current practice, most of these patients are being missed, as LDL-C is "at goal" & apoB isn't checked

->Regarding goals, we used evidence from untreated populations and from RCTs of individuals treated with LLTs to provide the following apoB thresholds at varying levels of risk: ->If apoB remains >70 for high risk or >60 for very high risk, intensification of Rx is recommended

To summarize, apoB is a precise, accurate, and well-validated measure that provides information not available on standard lipid panels Incorporation of apoB into clinical practice identifies patients at higher CV risk than appreciated who may warrant intensification of therapy